CL2020000705A1 - Anticuerpo anti-pacap. - Google Patents

Anticuerpo anti-pacap.

Info

Publication number
CL2020000705A1
CL2020000705A1 CL2020000705A CL2020000705A CL2020000705A1 CL 2020000705 A1 CL2020000705 A1 CL 2020000705A1 CL 2020000705 A CL2020000705 A CL 2020000705A CL 2020000705 A CL2020000705 A CL 2020000705A CL 2020000705 A1 CL2020000705 A1 CL 2020000705A1
Authority
CL
Chile
Prior art keywords
migraine
pacap antibody
antibodies
pain
treatment
Prior art date
Application number
CL2020000705A
Other languages
English (en)
Inventor
Chetankumar Natvarlal Patel
Catherine Brautigam Beidler
Michael Parvin Johnson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2020000705A1 publication Critical patent/CL2020000705A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SER REFIERE A ANTICUERPOS CONTRA EL PÉPTIDO ACTIVADOR DE LA ADENILATO CICLASA DE LA PITUITARIA, COMPOSICIONES QUE COMPRENDEN TALES ANTICUERPOS Y MÉTODOS PARA USAR TALES ANTICUERPOS PARA EL TRATAMIENTO DEL DOLOR INCLUYENDO CEFALEA Y/O MIGRAÑA.
CL2020000705A 2017-09-29 2020-03-18 Anticuerpo anti-pacap. CL2020000705A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762565278P 2017-09-29 2017-09-29

Publications (1)

Publication Number Publication Date
CL2020000705A1 true CL2020000705A1 (es) 2020-09-11

Family

ID=63794713

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000705A CL2020000705A1 (es) 2017-09-29 2020-03-18 Anticuerpo anti-pacap.

Country Status (25)

Country Link
US (3) US10519225B2 (es)
EP (1) EP3688035A1 (es)
JP (2) JP6952888B2 (es)
KR (1) KR102453573B1 (es)
CN (1) CN111164105B (es)
AR (1) AR113022A1 (es)
AU (1) AU2018341959B2 (es)
BR (1) BR112020003628A2 (es)
CA (1) CA3077304C (es)
CL (1) CL2020000705A1 (es)
CO (1) CO2020002170A2 (es)
CR (1) CR20200127A (es)
DO (1) DOP2020000060A (es)
EA (1) EA202090563A1 (es)
EC (1) ECSP20020293A (es)
IL (1) IL273529A (es)
JO (1) JOP20200069A1 (es)
MA (1) MA50654A (es)
MX (1) MX2020003563A (es)
NZ (1) NZ762312A (es)
PE (1) PE20201494A1 (es)
SG (1) SG11202002572YA (es)
TW (1) TWI701260B (es)
WO (1) WO2019067293A1 (es)
ZA (1) ZA202001058B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6752222B2 (ja) 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
WO2017181031A2 (en) * 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522159B1 (en) 1990-03-17 2001-12-12 Takeda Chemical Industries, Ltd. Antibody to pituitary adenylate cyclase activating peptide-pacap, hybridoma and assay for pacap
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
FR2826747B1 (fr) 2001-07-02 2005-02-25 Gemplus Card Int Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce
EP1583550A2 (en) 2003-01-16 2005-10-12 D. Collen Research Foundation vzw Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia
WO2012106407A2 (en) 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
JP6064861B2 (ja) 2013-03-05 2017-01-25 株式会社デンソー 熱電変換装置の製造方法
AU2014228924B2 (en) * 2013-03-15 2019-04-18 Amgen Inc. Human PAC1 antibodies
WO2015023890A1 (en) 2013-08-14 2015-02-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
JP6752222B2 (ja) 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
EP3390447A1 (en) * 2015-12-15 2018-10-24 Amgen Inc. Pacap antibodies and uses thereof
WO2017142961A1 (en) 2016-02-16 2017-08-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Treatment of traumatic brain injury or stroke

Also Published As

Publication number Publication date
ECSP20020293A (es) 2020-06-30
US20200131256A1 (en) 2020-04-30
KR20200040881A (ko) 2020-04-20
US10954292B2 (en) 2021-03-23
EA202090563A1 (ru) 2020-06-24
JOP20200069A1 (ar) 2020-04-28
TW201920280A (zh) 2019-06-01
US10519225B2 (en) 2019-12-31
CN111164105B (zh) 2023-07-04
PE20201494A1 (es) 2020-12-29
MX2020003563A (es) 2020-08-03
AU2018341959A1 (en) 2020-03-05
CN111164105A (zh) 2020-05-15
SG11202002572YA (en) 2020-04-29
JP7221352B2 (ja) 2023-02-13
WO2019067293A1 (en) 2019-04-04
TWI701260B (zh) 2020-08-11
CA3077304C (en) 2023-08-01
JP2020535167A (ja) 2020-12-03
CA3077304A1 (en) 2019-04-04
IL273529A (en) 2020-05-31
CO2020002170A2 (es) 2020-04-01
DOP2020000060A (es) 2020-08-15
KR102453573B1 (ko) 2022-10-12
AU2018341959B2 (en) 2021-11-25
JP2022000049A (ja) 2022-01-04
NZ762312A (en) 2022-11-25
JP6952888B2 (ja) 2021-10-27
EP3688035A1 (en) 2020-08-05
ZA202001058B (en) 2022-06-29
US20210171616A1 (en) 2021-06-10
MA50654A (fr) 2020-08-05
US20190100579A1 (en) 2019-04-04
CR20200127A (es) 2020-04-08
AR113022A1 (es) 2020-01-15
BR112020003628A2 (pt) 2020-09-01

Similar Documents

Publication Publication Date Title
CL2020000705A1 (es) Anticuerpo anti-pacap.
SV2018005662A (es) Moduladores del receptor x farnesoide
CO2018000078A2 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
CL2017000410A1 (es) Y-diquetonas para el tratamiento y la prevención de envejecimiento cutáneo y arrugas.
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
PE20181049A1 (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
GT201700188A (es) Anticuerpos contra tau y sus usos
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
EA202090457A1 (ru) Комбинированная терапия ласмидитаном и антагонистом cgrp для применения в лечении мигрени
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
BR112017004739A2 (pt) ligantes de hormônio folículo estimulante, complexo de ligante e gonadotrofina, uso de um ligante, e composição farmacêutica
CO2021004934A2 (es) Composiciones y métodos para tratar retinitis pigmentosa
CL2021001256A1 (es) Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer (divisional sol 201801470)
CL2020001846A1 (es) Anticuerpos pac1 y sus usos
EA201690732A1 (ru) Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций
EA201992883A1 (ru) АНТИТЕЛА К TrkB
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
EA202190504A1 (ru) Способы лечения псориаза
CL2019001924A1 (es) Composición fungicida efectiva contra alternaria en cítricos. (divisional solicitud 201701815)
EA201891739A1 (ru) ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH)
EA202090480A1 (ru) Композиция для контролируемой стимуляции яичников